Mocravimod Hydrochloride

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H26ClNO3S.ClH
Molecular Weight	480.447
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.NC(CO)(CO)CCC1=CC=C(SC2=CC=CC(OCC3=CC=CC=C3)=C2)C=C1Cl

InChI

InChIKey=MYIFLDFUXIHOCJ-UHFFFAOYSA-N

InChI=1S/C24H26ClNO3S.ClH/c25-23-14-22(10-9-19(23)11-12-24(26,16-27)17-28)30-21-8-4-7-20(13-21)29-15-18-5-2-1-3-6-18;/h1-10,13-14,27-28H,11-12,15-17,26H2;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C24H26ClNO3S
Molecular Weight	443.986
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132108 | http://www.kyorin-pharm.co.jp/en/news/docs/%E2%96%A0Extension%20of%20License%20Rights%20Regarding%20KRP-203.pdf

KYORIN Pharmaceutical has developed a new sphingosine 1-phosphate (S1P) receptor type 1 agonist, 2-amino-2-propanediol hydrochloride (KRP-203), for immunomodulation in autoimmune diseases and organ transplantation. This drug was in phase II clinical trial for the treatment Ulcerative Colitis, but this study was terminated. In addition, it has been investigated for the treatment of Cutaneous Lupus Erythematosus and Crohn's Disease, these phases II clinical trial studies were successfully completed.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sphingosine 1-phosphate receptor 1 7 Target ID: P21453 Gene ID: 1901.0 Gene Symbol: S1PR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16674913	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Ulcerative colitis 125 Sources: https://clinicaltrials.gov/ct2/show/NCT01375179	Primary	Phase II 1147	Unknown Approved Use Unknown
Cutaneous lupus erythematosus 2 Sources: https://clinicaltrials.gov/ct2/show/NCT01294774	Primary	Phase II 1147	Unknown Approved Use Unknown
Crohn's disease 64 Sources: http://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-132108	Primary	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
0.237 ng/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	1 mg/kg 1 times / day multiple, oral dose: 1 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: CYCLOSPORINE	CYCLOSPORINE	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.609 ng/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	3 mg/kg 1 times / day multiple, oral dose: 3 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: CYCLOSPORINE	CYCLOSPORINE	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
0.701 ng/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	3 mg/kg 1 times / day multiple, oral dose: 3 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: Tacrolimus	Tacrolimus	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
6.49 ng × h/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	1 mg/kg 1 times / day multiple, oral dose: 1 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: CYCLOSPORINE	CYCLOSPORINE	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
12.1 ng × h/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	3 mg/kg 1 times / day multiple, oral dose: 3 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: CYCLOSPORINE	CYCLOSPORINE	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
13.3 ng × h/mL CLINICAL TRIAL https://www.sciencedirect.com/science/article/pii/S2666636722017419#ecom0001	3 mg/kg 1 times / day multiple, oral dose: 3 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: Tacrolimus	Tacrolimus	MOCRAVIMOD plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1741

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1932	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=137275890	yes [IC50 20.931 uM]

Sourcing

Vendor/Aggregator	ID	URL
AK Scientific	7047AB	https://aksci.com/item_detail.php?cat=7047AB
Angene	AGN-PC-0S9BTK	http://www.angenechemical.com/productshow/AGN-PC-0S9BTK.html
AstaTech	51235	http://astatechinc.com/CPSResult.php?CRNO=51235
Axon MedChem	1615	https://www.axonmedchem.com/product/1615
BLD Pharm	BD00768881	http://www.bldpharm.com/search/Search.html?keyword=BD00768881
BOC Sciences	509088-69-1	http://www.bocsci.com/description.asp?cas=509088-69-1
Combi-Blocks	QP-3752	http://www.combi-blocks.com/cgi-bin/find.cgi?QP-3752
eMolecules	114917813	https://orderbb.emolecules.com/search/#?query=114917813
eMolecules	17405083	https://orderbb.emolecules.com/search/#?query=17405083
Hairui	HR118292	http://www.hairuichem.com/en/product/search.do?q=HR118292
KeyOrganics	AS-35752	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-35752
Matrix Scientific	95756	http://www.matrixscientific.com/095756.html
Molnova	M14745	https://www.molnova.com/en/serch-list.html?keywords=M14745
MolPort	MolPort-003-848-339	https://www.molport.com/shop/molecule-link/MolPort-003-848-339
MuseChem	I007529	https://www.musechem.com/product/I007529.html
MuseChem	I008126	https://www.musechem.com/product/I008126.html
ShangHai Biochempartner	BCP09029	http://www.biochempartner.com/search_BCP09029
Toronto Research Chemicals	T793765	https://www.trc-canada.com/product-detail/?CatNum=T793765

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

once daily

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:05:33 GMT 2025` Edited by `admin` on `Mon Mar 31 22:05:33 GMT 2025`
Record UNII	3YH0N35CE3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Mocravimod Hydrochloride

Official Name

English

KRP-203 hydrochloride

Preferred Name

English

KRP203 hydrochloride

Code

English

MOCRAVIMOD HYDROCHLORIDE [USAN]

Common Name

English

2-amino-2-[2-(2-chloro-4-{[3-(phenylmethoxy)phenyl]sulfanyl}phenyl)ethyl]propane-1,3-diol hydrochloride

Systematic Name

English

1,3-Propanediol, 2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy)phenyl]thio]phenyl]ethyl]-, hydrochloride (1:1)

Systematic Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

491315